|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
JP5324223B2
(ja)
|
2005-12-08 |
2013-10-23 |
トランセイブ， インク． |
肺感染症を治療する抗感染薬の脂質ベースの組成物及びその使用法
|
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
|
US8324277B2
(en)
|
2007-08-01 |
2012-12-04 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Nitrated-fatty acids modulation of type II diabetes
|
|
JP5697988B2
(ja)
|
2007-12-27 |
2015-04-08 |
プロチバ バイオセラピューティクス インコーポレイティッド |
干渉ｒｎａを使用したポロ様キナーゼ発現のサイレンシング方法
|
|
NZ588583A
(en)
|
2008-04-15 |
2012-08-31 |
Protiva Biotherapeutics Inc |
Novel lipid formulations for nucleic acid delivery
|
|
WO2009134383A2
(en)
|
2008-05-01 |
2009-11-05 |
Complexa Inc. |
Vinyl substituted fatty acids
|
|
US20140024713A1
(en)
|
2008-06-19 |
2014-01-23 |
University Of Utah Research Foundation |
Use of nitrated lipids for treatment of side effects of toxic medical therapies
|
|
EP2299997A4
(en)
|
2008-06-19 |
2012-01-11 |
Univ Utah Res Found |
USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES
|
|
JP5777519B2
(ja)
|
2008-10-09 |
2015-09-09 |
テクミラ ファーマシューティカルズ コーポレイション |
改良されたアミノ脂質および核酸の送達方法
|
|
AU2009307677C1
(en)
*
|
2008-10-20 |
2022-09-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
|
AU2015249072C1
(en)
*
|
2008-10-20 |
2022-10-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
|
MX2011004859A
(es)
|
2008-11-07 |
2011-08-03 |
Massachusetts Inst Technology |
Lipidoides de aminoalcohol y usos de los mismos.
|
|
US8722082B2
(en)
|
2008-11-10 |
2014-05-13 |
Tekmira Pharmaceuticals Corporation |
Lipids and compositions for the delivery of therapeutics
|
|
EP4241767B1
(en)
|
2008-11-10 |
2024-10-23 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
|
US20120101148A1
(en)
*
|
2009-01-29 |
2012-04-26 |
Alnylam Pharmaceuticals, Inc. |
lipid formulation
|
|
AU2010223967B2
(en)
*
|
2009-03-12 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
|
CA2760706C
(en)
*
|
2009-05-05 |
2019-08-06 |
Alnylam Pharmaceuticals, Inc. |
Methods of delivering oligonucleotides to immune cells
|
|
TR201811076T4
(tr)
*
|
2009-06-10 |
2018-08-27 |
Arbutus Biopharma Corp |
Geliştirilmiş lipit formulasyonu.
|
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
|
AU2010260148A1
(en)
*
|
2009-06-15 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated dsRNA targeting the PCSK9 gene
|
|
US8283333B2
(en)
|
2009-07-01 |
2012-10-09 |
Protiva Biotherapeutics, Inc. |
Lipid formulations for nucleic acid delivery
|
|
US8236943B2
(en)
|
2009-07-01 |
2012-08-07 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein B
|
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
|
EP3045167A1
(en)
|
2009-07-31 |
2016-07-20 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Keto fatty acids as anti-inflammatory agents
|
|
WO2011022460A1
(en)
|
2009-08-20 |
2011-02-24 |
Merck Sharp & Dohme Corp. |
Novel cationic lipids with various head groups for oligonucleotide delivery
|
|
CA2775092A1
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
CA2781276A1
(en)
|
2009-10-02 |
2011-04-07 |
Complexa, Inc. |
Heteroatom containing substituted fatty acids
|
|
US9101643B2
(en)
|
2009-11-03 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
|
|
PL3338765T3
(pl)
|
2009-12-01 |
2019-06-28 |
Translate Bio, Inc. |
Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych
|
|
WO2011088309A1
(en)
*
|
2010-01-14 |
2011-07-21 |
Regulus Therapeutics Inc. |
Microrna compositions and methods
|
|
EP2525781A1
(en)
|
2010-01-22 |
2012-11-28 |
Schering Corporation |
Novel cationic lipids for oligonucleotide delivery
|
|
WO2011127255A1
(en)
|
2010-04-08 |
2011-10-13 |
Merck Sharp & Dohme Corp. |
Preparation of lipid nanoparticles
|
|
US9408914B2
(en)
|
2010-04-28 |
2016-08-09 |
Kyowa Hakko Kirin Co., Ltd. |
Cationic lipid
|
|
JP5902617B2
(ja)
*
|
2010-04-28 |
2016-04-13 |
協和発酵キリン株式会社 |
カチオン性脂質
|
|
WO2011141703A1
(en)
*
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
US10077232B2
(en)
|
2010-05-12 |
2018-09-18 |
Arbutus Biopharma Corporation |
Cyclic cationic lipids and methods of use
|
|
US20130123338A1
(en)
*
|
2010-05-12 |
2013-05-16 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
|
US8802863B2
(en)
|
2010-05-24 |
2014-08-12 |
Sirna Therapeutics, Inc. |
Amino alcohol cationic lipids for oligonucleotide delivery
|
|
CA2800401C
(en)
|
2010-06-03 |
2020-09-15 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
WO2012000104A1
(en)
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
ES2646669T3
(es)
|
2010-07-06 |
2017-12-14 |
Glaxosmithkline Biologicals Sa |
Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
|
|
SI2591114T1
(sl)
|
2010-07-06 |
2016-10-28 |
Glaxosmithkline Biologicals S.A. |
Imunizacija velikih sesalcev z majhnimi odmerki RNA
|
|
AU2011276234B2
(en)
|
2010-07-06 |
2016-02-25 |
Glaxosmithkline Biologicals S.A. |
Liposomes with lipids having an advantageous pKa- value for RNA delivery
|
|
US11291635B2
(en)
|
2010-07-06 |
2022-04-05 |
Glaxosmithkline Biological Sa |
Virion-like delivery particles for self-replicating RNA molecules
|
|
US20130323269A1
(en)
*
|
2010-07-30 |
2013-12-05 |
Muthiah Manoharan |
Methods and compositions for delivery of active agents
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2606134B1
(en)
|
2010-08-17 |
2019-04-10 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US9233997B2
(en)
|
2010-08-26 |
2016-01-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
|
|
US9193827B2
(en)
|
2010-08-26 |
2015-11-24 |
Massachusetts Institute Of Technology |
Poly(beta-amino alcohols), their preparation, and uses thereof
|
|
WO2012031043A1
(en)
|
2010-08-31 |
2012-03-08 |
Novartis Ag |
Pegylated liposomes for delivery of immunogen-encoding rna
|
|
KR20130100278A
(ko)
|
2010-08-31 |
2013-09-10 |
머크 샤프 앤드 돔 코포레이션 |
올리고뉴클레오티드의 전달을 위한 신규 단일 화학 존재물 및 방법
|
|
WO2012031205A2
(en)
|
2010-09-03 |
2012-03-08 |
The Brigham And Women's Hospital, Inc. |
Lipid-polymer hybrid particles
|
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
|
MX349088B
(es)
|
2010-09-20 |
2017-07-10 |
Merck Sharp & Dohme |
Lípidos catiónicos novedosos de bajo peso molecular para la entrega de oligonucleótidos.
|
|
KR20130114115A
(ko)
|
2010-09-30 |
2013-10-16 |
머크 샤프 앤드 돔 코포레이션 |
올리고뉴클레오티드 전달을 위한 저분자량 양이온성 지질
|
|
ES3005233T3
(en)
|
2010-10-01 |
2025-03-14 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
EP3520813B1
(en)
|
2010-10-11 |
2023-04-19 |
GlaxoSmithKline Biologicals S.A. |
Antigen delivery platforms
|
|
CN103153347A
(zh)
|
2010-10-21 |
2013-06-12 |
默沙东公司 |
用于寡核苷酸递送的新型低分子量阳离子脂质
|
|
EP3766975A1
(en)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
|
WO2012061259A2
(en)
|
2010-11-05 |
2012-05-10 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
|
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
|
US9238716B2
(en)
|
2011-03-28 |
2016-01-19 |
Massachusetts Institute Of Technology |
Conjugated lipomers and uses thereof
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
DK3336082T3
(da)
|
2011-06-08 |
2020-04-27 |
Translate Bio Inc |
Spaltelige lipider
|
|
PT2717893T
(pt)
|
2011-06-08 |
2019-08-20 |
Translate Bio Inc |
Composições de nanopartículas lipídicas e métodos para transferência de arnm
|
|
EP3854413A1
(en)
|
2011-07-06 |
2021-07-28 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
|
EP4014966A1
(en)
|
2011-07-06 |
2022-06-22 |
GlaxoSmithKline Biologicals S.A. |
Liposomes having useful n:p ratio for delivery of rna molecules
|
|
EP2744491B1
(en)
|
2011-08-19 |
2020-07-29 |
The University of Utah Research Foundation |
Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
|
|
US9126966B2
(en)
*
|
2011-08-31 |
2015-09-08 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use thereof
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2763701B1
(en)
|
2011-10-03 |
2018-12-19 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
US9271952B2
(en)
*
|
2011-10-11 |
2016-03-01 |
Complexa, Inc. |
Compositions and methods for treating nephropathy
|
|
KR20150000461A
(ko)
|
2011-10-27 |
2015-01-02 |
메사추세츠 인스티튜트 오브 테크놀로지 |
약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
|
|
MY167390A
(en)
|
2011-11-18 |
2018-08-16 |
Alnylam Pharmaceuticals Inc |
Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
|
|
US9463247B2
(en)
*
|
2011-12-07 |
2016-10-11 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
|
WO2013086373A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
ES3065854T3
(en)
|
2011-12-07 |
2026-05-08 |
Alnylam Pharmaceuticals Inc |
Biodegradable lipids for the delivery of active agents
|
|
JP2015501844A
(ja)
|
2011-12-16 |
2015-01-19 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
CN104023751B
(zh)
|
2012-01-27 |
2016-11-09 |
弗·哈夫曼-拉罗切有限公司 |
靶向递送至表达vla-4的细胞的整联蛋白拮抗剂结合物
|
|
MX2014008373A
(es)
|
2012-01-27 |
2014-09-26 |
Hoffmann La Roche |
Conjugados antagonistas de integrina para suministro dirigido a celulas que expresan alfa-v-beta-3.
|
|
CA2857127A1
(en)
|
2012-01-27 |
2013-08-01 |
F. Hoffmann-La Roche Ag |
Integrin antagonist conjugates for targeted delivery to cells expressing lfa-1
|
|
BR112014015753A8
(pt)
|
2012-01-27 |
2017-07-04 |
Hoffmann La Roche |
derivado do polímero da quitosana, composição farmacêutica, método para o tratamento, utilização e presente invenção
|
|
DK2817287T3
(da)
|
2012-02-24 |
2019-01-02 |
Arbutus Biopharma Corp |
Trialkyl kationisk lipid og metoder til anvendelse deraf
|
|
CN102600173B
(zh)
*
|
2012-03-02 |
2013-05-29 |
海南美兰史克制药有限公司 |
氨氯地平/贝那普利药物组合物脂质体固体制剂
|
|
US10322089B2
(en)
*
|
2012-03-14 |
2019-06-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nanoparticles, nanoparticle delivery methods, and systems of delivery
|
|
WO2013143555A1
(en)
*
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
EP3865123A1
(en)
|
2012-03-29 |
2021-08-18 |
Translate Bio, Inc. |
Lipid-derived neutral nanoparticles
|
|
ES2762873T3
(es)
*
|
2012-03-29 |
2020-05-26 |
Translate Bio Inc |
Lípidos catiónicos ionizables
|
|
CN108949772A
(zh)
*
|
2012-04-02 |
2018-12-07 |
现代泰克斯公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9402816B2
(en)
|
2012-04-19 |
2016-08-02 |
Sima Therapeutics, Inc. |
Diester and triester based low molecular weight, biodegradeable cationic lipids for oligonucleotide delivery
|
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
|
WO2013185069A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Pulmonary delivery of mrna to non-lung target cells
|
|
WO2013185067A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
US9415109B2
(en)
|
2012-07-06 |
2016-08-16 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
|
TW201726599A
(zh)
|
2012-07-06 |
2017-08-01 |
協和醱酵麒麟有限公司 |
陽離子性脂質
|
|
EP2882706A1
(en)
|
2012-08-13 |
2015-06-17 |
Massachusetts Institute of Technology |
Amine-containing lipidoids and uses thereof
|
|
WO2014028429A2
(en)
|
2012-08-14 |
2014-02-20 |
Moderna Therapeutics, Inc. |
Enzymes and polymerases for the synthesis of rna
|
|
ES2921623T3
(es)
|
2012-11-26 |
2022-08-30 |
Modernatx Inc |
ARN modificado terminalmente
|
|
MX2015006681A
(es)
|
2012-11-29 |
2016-04-06 |
Insmed Inc |
Formulaciones de vancomicina estabilizadas.
|
|
EP2929035A1
(en)
|
2012-12-07 |
2015-10-14 |
Shire Human Genetic Therapies, Inc. |
Lipidic nanoparticles for mrna delivering
|
|
ES2981185T3
(es)
|
2013-03-14 |
2024-10-07 |
Translate Bio Inc |
Métodos para la purificación de ARN mensajero
|
|
ES2882110T3
(es)
|
2013-03-14 |
2021-12-01 |
Translate Bio Inc |
Métodos y composiciones para administrar anticuerpos codificados con ARNm
|
|
EP2968586B1
(en)
|
2013-03-14 |
2018-07-25 |
Translate Bio, Inc. |
Cftr mrna compositions and related methods and uses
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
EP4614148A3
(en)
|
2013-03-15 |
2025-12-17 |
Translate Bio, Inc. |
Synergistic enhancement of the delivery of nucleic acids via blended formulations
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
WO2014179562A1
(en)
|
2013-05-01 |
2014-11-06 |
Massachusetts Institute Of Technology |
1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
|
|
TW201534578A
(zh)
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
US11224642B2
(en)
|
2013-10-22 |
2022-01-18 |
Translate Bio, Inc. |
MRNA therapy for argininosuccinate synthetase deficiency
|
|
CA2928040A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Cns delivery of mrna and uses thereof
|
|
WO2015061467A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Lipid formulations for delivery of messenger rna
|
|
MX2016005239A
(es)
|
2013-10-22 |
2016-08-12 |
Shire Human Genetic Therapies |
Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
|
|
CA3236835A1
(en)
|
2013-11-22 |
2015-05-28 |
Mina Therapeutics Limited |
C/ebp alpha short activating rna compositions and methods of use
|
|
JP6527516B2
(ja)
|
2013-12-03 |
2019-06-05 |
ノースウェスタン ユニバーシティ |
リポソーム粒子、前述のものを作製する方法及びその使用
|
|
CN105916839B
(zh)
*
|
2014-01-09 |
2018-09-18 |
卫材R&D管理有限公司 |
阳离子性脂质
|
|
WO2015130584A2
(en)
|
2014-02-25 |
2015-09-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
PT3122878T
(pt)
|
2014-03-24 |
2019-02-01 |
Translate Bio Inc |
Terapia de arnm para o tratamento de doenças oculares
|
|
DK3134131T3
(en)
|
2014-04-23 |
2022-02-07 |
Modernatx Inc |
Nucleic acid vaccines
|
|
JP6571679B2
(ja)
|
2014-04-25 |
2019-09-04 |
トランスレイト バイオ， インコーポレイテッド |
メッセンジャーｒｎａの精製方法
|
|
SMT202000516T1
(it)
|
2014-05-15 |
2020-11-10 |
Insmed Inc |
Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari
|
|
CN105085295A
(zh)
*
|
2014-05-23 |
2015-11-25 |
上海交通大学 |
氨甲环酸的两亲性衍生物及其用途
|
|
CN105085292B
(zh)
*
|
2014-05-23 |
2017-12-15 |
上海交通大学 |
3‑((2‑(二甲氨基)乙烷基)(甲基)氨基)丙酸的两亲性衍生物及其用途
|
|
US10022455B2
(en)
|
2014-05-30 |
2018-07-17 |
Translate Bio, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
|
EP3164113B1
(en)
|
2014-06-04 |
2019-03-27 |
Exicure, Inc. |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
|
CA2952824C
(en)
|
2014-06-24 |
2023-02-21 |
Shire Human Genetic Therapies, Inc. |
Stereochemically enriched compositions for delivery of nucleic acids
|
|
IL316479A
(en)
|
2014-06-25 |
2024-12-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
|
|
EP3162794B1
(en)
|
2014-06-30 |
2020-09-16 |
Kyowa Kirin Co., Ltd. |
Alkyl substituted azetidines as cationic lipid
|
|
CA2953265C
(en)
|
2014-07-02 |
2023-09-26 |
Shire Human Genetic Therapies, Inc. |
Encapsulation of messenger rna
|
|
WO2016004202A1
(en)
|
2014-07-02 |
2016-01-07 |
Massachusetts Institute Of Technology |
Polyamine-fatty acid derived lipidoids and uses thereof
|
|
GB201414464D0
(en)
|
2014-08-14 |
2014-10-01 |
Technion Res & Dev Foundation |
Compositions and methods for therapeutics prescreening
|
|
WO2016028940A1
(en)
|
2014-08-19 |
2016-02-25 |
Northwestern University |
Protein/oligonucleotide core-shell nanoparticle therapeutics
|
|
EP4137138A1
(en)
|
2014-08-29 |
2023-02-22 |
Alnylam Pharmaceuticals, Inc. |
Methods of treating transthyretin (ttr) mediated amyloidosis
|
|
MA56412A
(fr)
|
2014-12-05 |
2022-05-04 |
Translate Bio Inc |
Thérapie par l'arn messager pour le traitement des maladies articulaires
|
|
JP6929791B2
(ja)
|
2015-02-09 |
2021-09-01 |
デューク ユニバーシティ |
エピゲノム編集のための組成物および方法
|
|
WO2016149508A1
(en)
|
2015-03-19 |
2016-09-22 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for pompe disease
|
|
US11298326B2
(en)
|
2015-03-24 |
2022-04-12 |
Kyowa Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticles
|
|
CN107567497A
(zh)
|
2015-04-17 |
2018-01-09 |
库瑞瓦格股份公司 |
Rna的冻干
|
|
JP2018526321A
(ja)
|
2015-04-27 |
2018-09-13 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ
|
|
CA2984512A1
(en)
|
2015-05-06 |
2016-11-10 |
Benitec Biopharma Limited |
Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
|
|
CN104803863B
(zh)
*
|
2015-05-08 |
2016-07-20 |
厦门成坤生物技术有限公司 |
阳离子类脂化合物及其制备方法
|
|
SG10201910431RA
(en)
|
2015-05-20 |
2020-01-30 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
WO2016184576A2
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
ES2949540T3
(es)
|
2015-06-19 |
2023-09-29 |
Massachusetts Inst Technology |
2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula
|
|
HUE067372T2
(hu)
|
2015-06-29 |
2024-10-28 |
Acuitas Therapeutics Inc |
Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
|
|
BR112018000254A2
(pt)
|
2015-07-07 |
2018-09-04 |
H Lundbeck As |
inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas
|
|
AU2016291228B2
(en)
*
|
2015-07-09 |
2020-04-09 |
Insmed Incorporated |
Compositions and methods for treating lung diseases and lung injury
|
|
MA42502A
(fr)
|
2015-07-21 |
2018-05-30 |
Modernatx Inc |
Vaccins contre une maladie infectieuse
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
JP6896703B2
(ja)
|
2015-07-31 |
2021-06-30 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ＴＴＲ関連疾患を治療または予防するためのトランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物およびその使用方法
|
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
WO2017035278A1
(en)
|
2015-08-24 |
2017-03-02 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
|
RS63030B1
(sr)
|
2015-09-17 |
2022-04-29 |
Modernatx Inc |
Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
|
|
IL258476B2
(en)
|
2015-10-02 |
2023-04-01 |
Complexa Inc |
Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
|
|
EP3359670B2
(en)
|
2015-10-05 |
2024-02-14 |
ModernaTX, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
CN108473969B9
(zh)
|
2015-10-14 |
2024-08-23 |
川斯勒佰尔公司 |
用于增强生产的rna相关酶的修饰
|
|
MD3718565T2
(ro)
|
2015-10-22 |
2022-09-30 |
Modernatx Inc |
Vaccinuri împotriva virusului respirator
|
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
WO2017070601A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
AU2016342376A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Sexually transmitted disease vaccines
|
|
RS63986B1
(sr)
|
2015-10-28 |
2023-03-31 |
Acuitas Therapeutics Inc |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
WO2017095967A2
(en)
|
2015-11-30 |
2017-06-08 |
Duke University |
Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
|
|
CA3007955A1
(en)
|
2015-12-10 |
2017-06-15 |
Modernatx, Inc. |
Lipid nanoparticles for delivery of therapeutic agents
|
|
CN106883158B
(zh)
*
|
2015-12-15 |
2019-08-23 |
中国科学院广州生物医药与健康研究院 |
生物可降解的氨基脂质类化合物及其制备方法和应用
|
|
JP7114465B2
(ja)
|
2015-12-22 |
2022-08-08 |
モデルナティエックス インコーポレイテッド |
薬剤の細胞内送達のための化合物および組成物
|
|
TW201726614A
(zh)
|
2015-12-25 |
2017-08-01 |
Kyowa Hakko Kirin Co Ltd |
作為陽離子性脂質之化合物
|
|
CN105622473B
(zh)
*
|
2016-02-06 |
2017-07-25 |
吴国球 |
一种阳离子氨基脂质及其合成方法和用途
|
|
US20190046638A1
(en)
|
2016-04-01 |
2019-02-14 |
Checkmate Pharmaceuticals, Inc. |
Fc RECEPTOR-MEDIATED DRUG DELIVERY
|
|
KR102369898B1
(ko)
|
2016-04-08 |
2022-03-03 |
트랜슬레이트 바이오 인코포레이티드 |
다량체 코딩 핵산 및 그 용도
|
|
EP3443081A4
(en)
|
2016-04-13 |
2019-10-30 |
Duke University |
CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
|
|
CN109219659B
(zh)
|
2016-04-14 |
2022-09-09 |
贝尼泰克生物制药有限公司 |
用于治疗眼咽型肌营养不良(opmd)的试剂及其用途
|
|
JP7186094B2
(ja)
|
2016-05-06 |
2022-12-08 |
イグジキュア オペレーティング カンパニー |
インターロイキン１７受容体ｍＲＮＡの特異的ノックダウンのためのアンチセンスオリゴヌクレオチド（ＡＳＯ）を提示するリポソーム系球状核酸（ＳＮＡ）構築物
|
|
AU2017267634C1
(en)
*
|
2016-05-16 |
2022-05-26 |
The Board Of Regents Of The University Of Texas System |
Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
|
|
US20170354672A1
(en)
*
|
2016-05-16 |
2017-12-14 |
The Board Of Regents Of The University Of Texas System |
Compositions for the delivery of trna as nanoparticles and methods of use therewith
|
|
US12128113B2
(en)
|
2016-05-18 |
2024-10-29 |
Modernatx, Inc. |
Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
|
|
JP7088911B2
(ja)
|
2016-05-18 |
2022-06-21 |
モデルナティエックス インコーポレイテッド |
リラキシンをコードするポリヌクレオチド
|
|
CN109312313A
(zh)
|
2016-06-13 |
2019-02-05 |
川斯勒佰尔公司 |
用于治疗鸟氨酸转氨甲酰酶缺乏症的信使rna疗法
|
|
WO2017222016A1
(ja)
|
2016-06-24 |
2017-12-28 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
カチオン性脂質
|
|
AU2017286980B2
(en)
*
|
2016-06-30 |
2023-10-26 |
Arbutus Biopharma Corporation |
Compositions and methods for delivering messenger RNA
|
|
EP4275747A3
(en)
|
2016-07-19 |
2024-01-24 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
CA3025812A1
(en)
|
2016-08-19 |
2018-02-22 |
Curevac Ag |
Rna for cancer therapy
|
|
WO2018062233A1
(ja)
|
2016-09-27 |
2018-04-05 |
協和発酵キリン株式会社 |
カチオン性脂質としての化合物
|
|
WO2018062413A1
(ja)
*
|
2016-09-28 |
2018-04-05 |
協和発酵キリン株式会社 |
核酸含有脂質ナノ粒子
|
|
AU2017345766A1
(en)
|
2016-10-21 |
2019-05-16 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US20190314486A1
(en)
|
2016-10-21 |
2019-10-17 |
Merck Sharp & Dohme Corp. |
Influenza hemagglutinin protein vaccines
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
JP7560946B2
(ja)
|
2016-11-10 |
2024-10-03 |
トランスレイト バイオ， インコーポレイテッド |
メッセンジャーｒｎａの皮下送達
|
|
MA46762A
(fr)
|
2016-11-10 |
2019-09-18 |
Translate Bio Inc |
Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnm
|
|
CN110167587A
(zh)
|
2016-11-11 |
2019-08-23 |
摩登纳特斯有限公司 |
流感疫苗
|
|
US11542490B2
(en)
|
2016-12-08 |
2023-01-03 |
CureVac SE |
RNAs for wound healing
|
|
EP3551193A4
(en)
|
2016-12-08 |
2020-08-19 |
Modernatx, Inc. |
NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
|
|
EP3808380A1
(en)
|
2016-12-08 |
2021-04-21 |
CureVac AG |
Rna for treatment or prophylaxis of a liver disease
|
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
|
WO2018115507A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Henipavirus vaccine
|
|
US11464847B2
(en)
|
2016-12-23 |
2022-10-11 |
Curevac Ag |
Lassa virus vaccine
|
|
FI3565891T3
(fi)
|
2017-01-09 |
2023-07-04 |
Whitehead Inst Biomedical Res |
Menetelmiä geeniekspression muuttamiseksi häiritsemällä säätelysilmukoita muodostavia transkriptiotekijämultimeerejä
|
|
BR112019014314A2
(pt)
|
2017-01-11 |
2020-02-18 |
The Trustees Of The University Of Pennsylvania |
Composição, e, método de indução de uma resposta imune adaptativa contra vírus zika.
|
|
WO2018151816A1
(en)
|
2017-02-16 |
2018-08-23 |
Modernatx, Inc. |
High potency immunogenic compositions
|
|
AU2018224326B2
(en)
|
2017-02-27 |
2024-01-04 |
Translate Bio, Inc. |
Novel codon-optimized CFTR mRNA
|
|
WO2018165257A1
(en)
|
2017-03-07 |
2018-09-13 |
Translate Bio, Inc. |
Polyanionic delivery of nucleic acids
|
|
KR20190132405A
(ko)
|
2017-03-15 |
2019-11-27 |
모더나티엑스, 인크. |
치료제의 세포내 전달을 위한 화합물 및 조성물
|
|
CA3056133A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
ES3020935T3
(en)
|
2017-03-15 |
2025-05-23 |
Modernatx Inc |
Lipid nanoparticle formulation
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
MA47787A
(fr)
|
2017-03-15 |
2020-01-22 |
Modernatx Inc |
Vaccin contre le virus respiratoire syncytial
|
|
WO2018170347A1
(en)
|
2017-03-17 |
2018-09-20 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
|
US20200085944A1
(en)
|
2017-03-17 |
2020-03-19 |
Curevac Ag |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
|
CN110914433A
(zh)
|
2017-03-24 |
2020-03-24 |
库尔维科公司 |
编码crispr相关蛋白质的核酸及其用途
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
CA3061326A1
(en)
|
2017-04-27 |
2018-11-01 |
The Johns Hopkins University |
Nucleoside-modified mrna-lipid nanoparticle lineage vaccine for hepatitis c virus
|
|
ES2981244T3
(es)
|
2017-04-28 |
2024-10-07 |
Acuitas Therapeutics Inc |
Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
|
|
WO2018209270A1
(en)
|
2017-05-11 |
2018-11-15 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (snas)
|
|
MX2019013752A
(es)
|
2017-05-16 |
2020-07-20 |
Translate Bio Inc |
Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
|
|
US11939600B2
(en)
|
2017-05-31 |
2024-03-26 |
Arcturus Therapeutics, Inc. |
Compositions and methods for treating phenylketonuria
|
|
US11377643B2
(en)
|
2017-05-31 |
2022-07-05 |
Ultragenyx Pharmaceutical Inc. |
Therapeutics for glycogen storage disease type III
|
|
WO2018222890A1
(en)
|
2017-05-31 |
2018-12-06 |
Arcturus Therapeutics, Inc. |
Synthesis and structure of high potency rna therapeutics
|
|
US12077501B2
(en)
|
2017-06-14 |
2024-09-03 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
WO2018232357A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna formulations
|
|
EP3641834B1
(en)
|
2017-06-19 |
2023-10-04 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of friedreich's ataxia
|
|
BR112019028280A2
(pt)
|
2017-07-04 |
2020-07-14 |
Curevac Ag |
moléculas de ácido nucleico
|
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
|
EP3662913A4
(en)
|
2017-08-04 |
2021-06-30 |
Kyowa Kirin Co., Ltd. |
Nucleic-acid-containing lipid nanoparticles
|
|
US11639329B2
(en)
|
2017-08-16 |
2023-05-02 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
EP4501322A3
(en)
|
2017-08-17 |
2025-04-16 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
EP3673069A1
(en)
|
2017-08-22 |
2020-07-01 |
CureVac AG |
Bunyavirales vaccine
|
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
|
EP4219715A3
(en)
|
2017-09-08 |
2023-09-06 |
MiNA Therapeutics Limited |
Stabilized cebpa sarna compositions and methods of use
|
|
CA3075205A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
Stabilized hnf4a sarna compositions and methods of use
|
|
US10653767B2
(en)
|
2017-09-14 |
2020-05-19 |
Modernatx, Inc. |
Zika virus MRNA vaccines
|
|
KR20200089656A
(ko)
|
2017-09-19 |
2020-07-27 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
|
|
SG11202002186VA
(en)
|
2017-10-19 |
2020-05-28 |
Curevac Ag |
Novel artificial nucleic acid molecules
|
|
US11692002B2
(en)
|
2017-11-08 |
2023-07-04 |
CureVac SE |
RNA sequence adaptation
|
|
EP3723796A1
(en)
|
2017-12-13 |
2020-10-21 |
CureVac AG |
Flavivirus vaccine
|
|
US11167043B2
(en)
|
2017-12-20 |
2021-11-09 |
Translate Bio, Inc. |
Composition and methods for treatment of ornithine transcarbamylase deficiency
|
|
EP3733647B1
(en)
|
2017-12-27 |
2022-06-15 |
Eisai R&D Management Co., Ltd. |
Cationic lipid
|
|
MX2020006843A
(es)
|
2017-12-27 |
2020-09-03 |
Takeda Pharmaceuticals Co |
Nanoparticula de lipido que contiene acido nucleico y uso de la misma.
|
|
US12509492B2
(en)
|
2018-01-19 |
2025-12-30 |
Duke University |
Genome engineering with CRISPR-Cas systems in eukaryotes
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
JP7541482B2
(ja)
|
2018-01-29 |
2024-08-28 |
メルク・シャープ・アンド・ドーム・エルエルシー |
安定化ｒｓｖ ｆタンパク質およびその使用
|
|
WO2019152802A1
(en)
|
2018-02-02 |
2019-08-08 |
Translate Bio, Inc. |
Cationic polymers
|
|
WO2019155094A1
(en)
*
|
2018-02-12 |
2019-08-15 |
Interna Technologies B.V. |
Anticancer microrna and lipid formulations thereof
|
|
EP3752194A4
(en)
|
2018-02-13 |
2022-03-16 |
Checkmate Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY
|
|
WO2019191627A1
(en)
|
2018-03-30 |
2019-10-03 |
Insmed Incorporated |
Methods for continuous manufacture of liposomal drug products
|
|
WO2019193183A2
(en)
|
2018-04-05 |
2019-10-10 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
|
SG11202009647VA
(en)
|
2018-04-09 |
2020-10-29 |
Checkmate Pharmaceuticals |
Packaging oligonucleotides into virus-like particles
|
|
EP4242307A3
(en)
|
2018-04-12 |
2023-12-27 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
DE202019006199U1
(de)
|
2018-04-17 |
2026-01-12 |
CureVac SE |
Neue RSV-RNA-Moleküle und Zusammensetzungen für die Impfung
|
|
WO2019213398A1
(en)
|
2018-05-02 |
2019-11-07 |
Insmed Incorporated |
Methods for the manufacture of liposomal drug formulations
|
|
AU2019271132B2
(en)
|
2018-05-15 |
2026-02-05 |
Translate Bio, Inc. |
Subcutaneous delivery of messenger RNA
|
|
US11964051B2
(en)
|
2018-05-16 |
2024-04-23 |
Translate Bio, Inc. |
Ribose cationic lipids
|
|
AU2019275068B2
(en)
|
2018-05-24 |
2024-09-26 |
Translate Bio, Inc. |
Thioester cationic lipids
|
|
EP3801526B1
(en)
|
2018-05-25 |
2023-12-27 |
Imara Inc. |
Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one
|
|
WO2019232095A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Vitamin cationic lipids
|
|
US11547666B2
(en)
|
2018-05-30 |
2023-01-10 |
Translate Bio, Inc. |
Cationic lipids comprising a steroidal moiety
|
|
AU2019277361B2
(en)
|
2018-05-30 |
2025-04-24 |
Translate Bio, Inc. |
Messenger RNA vaccines and uses thereof
|
|
AU2019277355A1
(en)
|
2018-05-30 |
2020-12-17 |
Translate Bio, Inc. |
Phosphoester cationic lipids
|
|
US20210260178A1
(en)
|
2018-06-27 |
2021-08-26 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
|
KR20210056331A
(ko)
|
2018-07-23 |
2021-05-18 |
트랜슬레이트 바이오 인코포레이티드 |
전령 rna의 건조 분말 제형
|
|
CN118421617A
(zh)
|
2018-08-24 |
2024-08-02 |
川斯勒佰尔公司 |
用于纯化信使rna的方法
|
|
KR20210091120A
(ko)
|
2018-08-29 |
2021-07-21 |
트랜슬레이트 바이오 인코포레이티드 |
Mrna-로딩된 지질 나노입자를 제조하는 개선된 공정
|
|
CN112996512B
(zh)
|
2018-08-31 |
2025-01-03 |
卡都瑞恩医药公司 |
用于治疗镰状细胞病的pde9抑制剂
|
|
US12564645B2
(en)
|
2018-09-14 |
2026-03-03 |
Translate Bio, Inc. |
Methods for treatment of methylmalonic acidemia
|
|
US12151029B2
(en)
|
2018-09-19 |
2024-11-26 |
Modernatx, Inc. |
PEG lipids and uses thereof
|
|
AU2019345067A1
(en)
|
2018-09-19 |
2021-04-08 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
IL281615B2
(en)
|
2018-09-21 |
2026-01-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
EP3860561B1
(en)
|
2018-10-01 |
2023-06-21 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
CN113166783B
(zh)
|
2018-10-09 |
2024-10-11 |
不列颠哥伦比亚大学 |
包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
|
|
CN119876276A
(zh)
|
2018-10-18 |
2025-04-25 |
武田药品工业株式会社 |
T细胞的活化/增殖方法
|
|
US12583816B2
(en)
|
2018-10-18 |
2026-03-24 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
KR20210090634A
(ko)
|
2018-10-19 |
2021-07-20 |
트랜슬레이트 바이오 인코포레이티드 |
전령 rna의 무펌프 캡슐화
|
|
EA202191315A1
(ru)
*
|
2018-11-09 |
2021-09-08 |
Арбутус Биофарма Корпорэйшн |
Катионные липиды, содержащие кремний
|
|
EP3876914A2
(en)
|
2018-11-09 |
2021-09-15 |
Translate Bio, Inc. |
Messenger rna therapy for treatment of ocular diseases
|
|
AU2019374871B2
(en)
|
2018-11-09 |
2025-09-11 |
Translate Bio, Inc. |
PEG lipidoid compounds
|
|
WO2020097376A1
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
Multi-peg lipid compounds
|
|
KR102860605B1
(ko)
|
2018-11-09 |
2025-09-15 |
트랜슬레이트 바이오 인코포레이티드 |
에스테르, 티오에스테르, 이황화물, 및 무수물 모이어티가 삽입된 2,5-디옥소피페라진
|
|
AU2019378763B2
(en)
|
2018-11-12 |
2025-06-26 |
Translate Bio, Inc. |
Methods for inducing immune tolerance
|
|
EP3883917B1
(en)
|
2018-11-21 |
2024-01-24 |
Translate Bio, Inc. |
Cationic lipid compounds and compositions thereof for use in the delivery of messenger rna
|
|
EP3883592A1
(en)
|
2018-11-21 |
2021-09-29 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
|
|
PL3891274T3
(pl)
|
2018-12-06 |
2024-03-25 |
Arcturus Therapeutics, Inc. |
Kompozycje i sposoby leczenia niedoboru transkarbamylazy ornityny
|
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
|
CN113453707A
(zh)
|
2018-12-21 |
2021-09-28 |
库瑞瓦格股份公司 |
用于疟疾疫苗的rna
|
|
CN113412273B
(zh)
|
2019-01-07 |
2025-08-22 |
川斯勒佰尔公司 |
用于治疗原发性纤毛运动障碍的组合物和方法
|
|
JP7523449B2
(ja)
|
2019-01-11 |
2024-07-26 |
アクイタス セラピューティクス インコーポレイテッド |
活性剤の脂質ナノ粒子送達のための脂質
|
|
MX2021009245A
(es)
*
|
2019-01-31 |
2021-11-12 |
Modernatx Inc |
Metodos de preparacion de nanoparticulas lipidicas.
|
|
EP4491229A3
(en)
|
2019-02-08 |
2025-05-14 |
CureVac SE |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
WO2020190750A1
(en)
|
2019-03-15 |
2020-09-24 |
Modernatx, Inc. |
Hiv rna vaccines
|
|
US20220204994A1
(en)
|
2019-04-05 |
2022-06-30 |
Precision Biosciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
|
WO2020208361A1
(en)
|
2019-04-12 |
2020-10-15 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
US20220177423A1
(en)
|
2019-04-18 |
2022-06-09 |
Translate Bio, Inc. |
Cystine cationic lipids
|
|
ES2972014T3
(es)
|
2019-04-22 |
2024-06-10 |
Translate Bio Inc |
Lípidos catiónicos de tioéster
|
|
US12453759B2
(en)
|
2019-05-03 |
2025-10-28 |
Translate Bio, Inc. |
Di-thioester cationic lipids
|
|
EP3968952A1
(en)
|
2019-05-14 |
2022-03-23 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
JP7686574B2
(ja)
|
2019-05-22 |
2025-06-02 |
マサチューセッツ インスティテュート オブ テクノロジー |
環状ｒｎａ組成物及び方法
|
|
WO2020243540A1
(en)
|
2019-05-31 |
2020-12-03 |
Translate Bio, Inc. |
Macrocyclic lipids
|
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
|
WO2020257611A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Cationic lipids comprising an hydroxy moiety
|
|
AU2020297606B2
(en)
|
2019-06-21 |
2026-04-02 |
Translate Bio, Inc. |
Tricine and citric acid lipids
|
|
JP7699552B2
(ja)
*
|
2019-07-03 |
2025-06-27 |
ファクター バイオサイエンス インコーポレイテッド |
カチオン性脂質及びその使用
|
|
ES2992127T3
(es)
|
2019-07-08 |
2024-12-09 |
Translate Bio Inc |
Nanopartículas lipídicas cargadas de ARNm mejoradas y sus procesos de fabricación
|
|
CA3147875A1
(en)
|
2019-07-19 |
2021-01-28 |
Flagship Pioneering Innovations Vi, Llc |
Recombinase compositions and methods of use
|
|
JP7630904B2
(ja)
*
|
2019-07-23 |
2025-02-18 |
株式会社東芝 |
核酸導入キャリア、核酸導入キャリアセット、核酸導入組成物及び核酸導入方法
|
|
WO2021016430A1
(en)
|
2019-07-23 |
2021-01-28 |
Translate Bio, Inc. |
Stable compositions of mrna-loaded lipid nanoparticles and processes of making
|
|
EP4003397B1
(en)
|
2019-07-30 |
2025-02-26 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
|
|
US10501404B1
(en)
|
2019-07-30 |
2019-12-10 |
Factor Bioscience Inc. |
Cationic lipids and transfection methods
|
|
JP2022544412A
(ja)
|
2019-08-14 |
2022-10-18 |
キュアバック アーゲー |
免疫賦活特性が減少したｒｎａ組み合わせおよび組成物
|
|
MX2022003269A
(es)
|
2019-09-19 |
2022-07-04 |
Modernatx Inc |
Compuestos lipidicos de cola ramificada y composiciones para la administracion intracelular de agentes terapeuticos.
|
|
CA3155015A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2021055609A1
(en)
|
2019-09-20 |
2021-03-25 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
|
AU2020352552A1
(en)
|
2019-09-23 |
2022-03-17 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression
|
|
CN114391040A
(zh)
|
2019-09-23 |
2022-04-22 |
欧米茄治疗公司 |
用于调节载脂蛋白b(apob)基因表达的组合物和方法
|
|
JP7650873B2
(ja)
|
2019-10-09 |
2025-03-25 |
トランスレイト バイオ， インコーポレイテッド |
メッセンジャーｒｎａの組成物、方法および使用
|
|
US20220396556A1
(en)
*
|
2019-10-18 |
2022-12-15 |
The Trustees Of The University Of Pennsylvania |
Lipid and Lipid Nanoparticle Formulation for Drug Delivery
|
|
US20210145860A1
(en)
|
2019-10-21 |
2021-05-20 |
Translate Bio, Inc. |
Compositions, methods and uses of messenger rna
|
|
AU2020397956A1
(en)
|
2019-12-04 |
2022-07-07 |
Orna Therapeutics, Inc. |
Circular RNA compositions and methods
|
|
CN114901360A
(zh)
|
2019-12-20 |
2022-08-12 |
库瑞瓦格股份公司 |
用于递送核酸的新型脂质纳米颗粒
|
|
US12053551B2
(en)
|
2019-12-20 |
2024-08-06 |
Translate Bio, Inc. |
Process of preparing mRNA-loaded lipid nanoparticles
|
|
KR20220142432A
(ko)
|
2019-12-20 |
2022-10-21 |
트랜슬레이트 바이오 인코포레이티드 |
메신저 rna의 직장 전달
|
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
|
EP3886897A1
(en)
|
2020-02-04 |
2021-10-06 |
CureVac AG |
Coronavirus vaccine
|
|
BR112022015313A2
(pt)
|
2020-02-14 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Vacina de hpv
|
|
WO2021173840A1
(en)
|
2020-02-25 |
2021-09-02 |
Translate Bio, Inc. |
Improved processes of preparing mrna-loaded lipid nanoparticles
|
|
WO2021178510A1
(en)
|
2020-03-03 |
2021-09-10 |
Arcturus Therapeutics, Inc. |
Compositions and methods for the treatment of ornithine transcarbamylase deficiency
|
|
CA3171231A1
(en)
|
2020-03-09 |
2021-09-16 |
Sean Michael Sullivan |
Compositions and methods for inducing immune responses
|
|
WO2021183720A1
(en)
|
2020-03-11 |
2021-09-16 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
AU2021244555A1
(en)
|
2020-03-24 |
2022-11-24 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
|
WO2021195218A1
(en)
|
2020-03-24 |
2021-09-30 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
AU2021252164A1
(en)
|
2020-04-09 |
2022-12-15 |
Finncure Oy |
Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
|
|
US12194157B2
(en)
|
2020-04-09 |
2025-01-14 |
Finncure Oy |
Carrier for targeted delivery to a host
|
|
CA3176844A1
(en)
|
2020-05-01 |
2021-11-04 |
Carlos G. PEREZ-GARCIA |
Nucleic acids and methods of treatment for cystic fibrosis
|
|
WO2021226436A1
(en)
|
2020-05-07 |
2021-11-11 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding sars-cov-2 antigens
|
|
US12605399B2
(en)
|
2020-05-07 |
2026-04-21 |
Translate Bio, Inc. |
Compositions for CFTR MRNA therapy
|
|
EP4146680A1
(en)
|
2020-05-07 |
2023-03-15 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
US12514932B2
(en)
|
2020-05-14 |
2026-01-06 |
Translate Bio, Inc. |
PEG lipidoid compounds
|
|
EP4149425A1
(en)
|
2020-05-15 |
2023-03-22 |
Translate Bio, Inc. |
Lipid nanoparticle formulations for mrna delivery
|
|
US20240042015A1
(en)
|
2020-05-19 |
2024-02-08 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
TW202206097A
(zh)
|
2020-05-20 |
2022-02-16 |
美商旗艦先鋒創新有限責任公司 |
冠狀病毒抗原組成物及其用途
|
|
EP4153223A1
(en)
|
2020-05-20 |
2023-03-29 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
CN116322758A
(zh)
|
2020-05-29 |
2023-06-23 |
库尔维科欧洲股份公司 |
基于核酸的组合疫苗
|
|
CA3182026A1
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
|
IL298539A
(en)
|
2020-05-29 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Trem compositions and methods relating thereto
|
|
US20240307556A1
(en)
|
2020-07-02 |
2024-09-19 |
Maritime Therapeutics, Inc. |
Compositions and methods for reverse gene therapy
|
|
CA3188801A1
(en)
|
2020-07-08 |
2022-01-13 |
Janssen Sciences Ireland Unlimited Company |
Rna replicon vaccines against hbv
|
|
JP7798855B2
(ja)
|
2020-07-16 |
2026-01-14 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子に使用するためのカチオン性脂質
|
|
WO2022023284A1
(en)
|
2020-07-27 |
2022-02-03 |
Anjarium Biosciences Ag |
Compositions of dna molecules, methods of making therefor, and methods of use thereof
|
|
EP4172194A1
(en)
|
2020-07-31 |
2023-05-03 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|
|
TW202220637A
(zh)
*
|
2020-08-06 |
2022-06-01 |
美商現代公司 |
製備脂質奈米顆粒之方法
|
|
CN116171150A
(zh)
|
2020-08-14 |
2023-05-26 |
阿克丘勒斯治疗公司 |
冻干脂质纳米颗粒的方法
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
CA3170743A1
(en)
|
2020-08-31 |
2022-03-03 |
Susanne RAUCH |
Multivalent nucleic acid based coronavirus vaccines
|
|
EP4208196A1
(en)
|
2020-09-03 |
2023-07-12 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
EP4211247A4
(en)
|
2020-09-13 |
2024-11-13 |
Arcturus Therapeutics, Inc. |
ENCAPSULATION OF LARGE RNA IN LIPID NANOPARTICLES
|
|
WO2022076562A1
(en)
|
2020-10-06 |
2022-04-14 |
Translate Bio, Inc. |
Improved process and formulation of lipid nanoparticles
|
|
WO2022076547A1
(en)
|
2020-10-07 |
2022-04-14 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
|
US20220133631A1
(en)
|
2020-10-12 |
2022-05-05 |
Translate Bio, Inc. |
Process of preparing ice-based lipid nanoparticles
|
|
US20220110884A1
(en)
|
2020-10-12 |
2022-04-14 |
Translate Bio, Inc. |
Process of preparing mrna-loaded lipid nanoparticles
|
|
KR20230118715A
(ko)
|
2020-10-14 |
2023-08-11 |
조지 메이슨 리서치 파운데이션 인코포레이티드 |
이온화 가능 지질 및 이의 제조 및 사용 방법
|
|
AU2021373892A1
(en)
|
2020-11-09 |
2023-07-06 |
Translate Bio, Inc. |
Improved compositions for delivery of codon-optimized mrna
|
|
CA3200234A1
(en)
|
2020-11-25 |
2022-06-02 |
Daryl C. Drummond |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
|
CN116723829A
(zh)
|
2020-11-25 |
2023-09-08 |
翻译生物公司 |
稳定的液体脂质纳米颗粒配制品
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
US20240299309A1
(en)
|
2020-12-22 |
2024-09-12 |
CureVac SE |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
US20240156946A1
(en)
|
2020-12-22 |
2024-05-16 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
|
BR112023012377A2
(pt)
|
2020-12-23 |
2023-10-24 |
Flagship Pioneering Innovations Vi Llc |
Composições de trems modificadas e usos das mesmas
|
|
WO2022146654A1
(en)
|
2020-12-28 |
2022-07-07 |
Janssen Pharmaceuticals, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
|
JP2024504614A
(ja)
|
2021-01-14 |
2024-02-01 |
トランスレイト バイオ， インコーポレイテッド |
ｍＲＮＡがコードする抗体を送達する方法および組成物
|
|
EP4087938A2
(en)
|
2021-01-27 |
2022-11-16 |
CureVac AG |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
WO2022204549A1
(en)
|
2021-03-25 |
2022-09-29 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
|
|
CA3214137A1
(en)
|
2021-03-26 |
2022-09-29 |
Mina Therapeutics Limited |
Tmem173 sarna compositions and methods of use
|
|
MX2023011400A
(es)
|
2021-03-26 |
2023-10-09 |
Glaxosmithkline Biologicals Sa |
Composiciones inmunogenicas.
|
|
US20220325287A1
(en)
|
2021-03-31 |
2022-10-13 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
WO2022207862A2
(en)
|
2021-03-31 |
2022-10-06 |
Curevac Ag |
Syringes containing pharmaceutical compositions comprising rna
|
|
EP4323770A1
(en)
*
|
2021-04-12 |
2024-02-21 |
Institut Curie |
Folr2+ macrophages and anti-tumor immunity
|
|
WO2022225918A1
(en)
|
2021-04-19 |
2022-10-27 |
Translate Bio, Inc. |
Improved compositions for delivery of mrna
|
|
US20240358852A1
(en)
|
2021-04-20 |
2024-10-31 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
|
EP4329884A1
(en)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
WO2022232289A1
(en)
|
2021-04-27 |
2022-11-03 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
EP4334446A1
(en)
|
2021-05-03 |
2024-03-13 |
CureVac SE |
Improved nucleic acid sequence for cell type specific expression
|
|
EP4347577A4
(en)
*
|
2021-05-28 |
2025-09-03 |
Nanovation Therapeutics Inc |
KC2-TYPE LIPIDS
|
|
KR20220167770A
(ko)
|
2021-06-11 |
2022-12-21 |
주식회사 나이벡 |
타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드-지질의 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물
|
|
JP2024527541A
(ja)
|
2021-07-01 |
2024-07-25 |
トランスレイト バイオ， インコーポレイテッド |
Ｍｒｎａの送達のための組成物
|
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
EP4377457A1
(en)
|
2021-07-26 |
2024-06-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and uses thereof
|
|
WO2023010135A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
US20240342206A1
(en)
|
2021-07-30 |
2024-10-17 |
CureVac SE |
mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
|
|
EP4377459A2
(en)
|
2021-07-30 |
2024-06-05 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
TW202328445A
(zh)
|
2021-08-03 |
2023-07-16 |
美商艾拉倫製藥股份有限公司 |
甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物及其使用方法
|
|
CA3229064A1
(en)
|
2021-08-19 |
2023-02-23 |
Andrew Bett |
Thermostable lipid nanoparticle and methods of use thereof
|
|
CN113461577B
(zh)
*
|
2021-09-01 |
2021-12-14 |
中山大学附属第七医院(深圳) |
一种氨基脂质及其应用
|
|
CN115745942B
(zh)
*
|
2021-09-03 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
IL309505A
(en)
|
2021-09-03 |
2024-02-01 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
CN117940158A
(zh)
|
2021-09-03 |
2024-04-26 |
库瑞瓦格欧洲公司 |
用于核酸递送的包含磷脂酰丝氨酸的新型脂质纳米颗粒
|
|
CN115745941B
(zh)
*
|
2021-09-03 |
2025-07-01 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
CN115772089B
(zh)
*
|
2021-09-07 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
DK4271818T3
(da)
|
2021-09-17 |
2024-11-04 |
Flagship Pioneering Innovations Vi Llc |
Sammensætninger og fremgangsmåder til fremstilling af cirkulære polyribonukleotider
|
|
US20240417714A1
(en)
|
2021-10-18 |
2024-12-19 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
US20250027108A1
(en)
|
2021-10-29 |
2025-01-23 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
CN118541346A
(zh)
|
2021-11-08 |
2024-08-23 |
奥纳治疗公司 |
用于递送环状多核苷酸的脂质纳米颗粒组合物
|
|
AU2022388747A1
(en)
|
2021-11-10 |
2024-06-20 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
CN118900845A
(zh)
|
2021-11-24 |
2024-11-05 |
旗舰创业创新六公司 |
冠状病毒免疫原组合物及其用途
|
|
IL312965A
(en)
|
2021-11-24 |
2024-07-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and their uses
|
|
CA3238370A1
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovations Vi, Llc |
Varicella-zoster virus immunogen compositions and their uses
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
|
CA3242402A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
MX2024007307A
(es)
|
2021-12-17 |
2024-08-06 |
Flagship Pioneering Innovations Vi Llc |
Métodos de enriquecimiento de arn circular en condiciones desnaturalizantes.
|
|
AU2022417517A1
(en)
|
2021-12-22 |
2024-06-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
MX2024007870A
(es)
|
2021-12-23 |
2024-08-15 |
Flagship Pioneering Innovations Vi Llc |
Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos.
|
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
JP2025504404A
(ja)
|
2022-01-14 |
2025-02-12 |
アンジャリウム バイオサイエンシズ エージー |
Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法
|
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
|
US20250099614A1
(en)
|
2022-01-28 |
2025-03-27 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
AU2023235112A1
(en)
|
2022-03-14 |
2024-10-17 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
|
EP4499607A1
(en)
|
2022-03-25 |
2025-02-05 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
US20250205168A1
(en)
*
|
2022-03-28 |
2025-06-26 |
Nof Corporation |
Method for producing nucleic acid-encapsulated lipid nanoparticles, method for producing pharmaceutical composition containing said lipid nanoparticles, and method for introducing nucleic acid into cell or target cell
|
|
CN119654166A
(zh)
|
2022-04-01 |
2025-03-18 |
内诺维什疗法股份有限公司 |
mRNA递送方法及其组合物
|
|
WO2023196634A2
(en)
|
2022-04-08 |
2023-10-12 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
|
WO2023214405A1
(en)
|
2022-05-01 |
2023-11-09 |
Yeda Research And Development Co. Ltd. |
Reexpression of hnf4a to alleviate cancer-associated cachexia
|
|
US20250295687A1
(en)
|
2022-05-09 |
2025-09-25 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
|
TW202409283A
(zh)
|
2022-05-13 |
2024-03-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
雙股ｄｎａ組合物及相關方法
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
CA3248209A1
(en)
|
2022-05-25 |
2023-11-30 |
CureVac SE |
Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH)
|
|
EP4531819A2
(en)
|
2022-05-25 |
2025-04-09 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
|
AU2023283348A1
(en)
|
2022-06-07 |
2025-01-09 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
|
AR129560A1
(es)
|
2022-06-08 |
2024-09-04 |
Tidal Therapeutics Inc |
Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
|
|
WO2023250112A1
(en)
|
2022-06-22 |
2023-12-28 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
KR20250044484A
(ko)
|
2022-06-24 |
2025-03-31 |
튠 쎄라퓨틱스, 인코포레이티드 |
표적 유전자 억제를 통해 저밀도 지단백질을 감소시키기 위한 조성물, 시스템, 및 방법
|
|
US12297285B2
(en)
|
2022-06-24 |
2025-05-13 |
Orna Therapeutics, Inc. |
Circular RNA encoding chimeric antigen receptors targeting BCMA
|
|
CN120051297A
(zh)
|
2022-06-30 |
2025-05-27 |
因达普塔治疗公司 |
工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法
|
|
EP4554967A2
(en)
|
2022-07-12 |
2025-05-21 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
|
AU2023320333A1
(en)
|
2022-08-01 |
2025-01-16 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
WO2024040195A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
CN120435557A
(zh)
|
2022-08-19 |
2025-08-05 |
图恩疗法股份有限公司 |
通过靶向基因阻遏调节乙型肝炎病毒的组合物、系统和方法
|
|
US20260055426A1
(en)
|
2022-08-19 |
2026-02-26 |
Generation Bio Co. |
CLEAVABLE CLOSED-ENDED DNA (ceDNA) AND METHODS OF USE THEREOF
|
|
EP4581012A2
(en)
|
2022-08-31 |
2025-07-09 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
JPWO2024053648A1
(enExample)
|
2022-09-06 |
2024-03-14 |
|
|
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
|
CA3267272A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
FLU VIRUS VACCINES
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
CA3266203A1
(en)
*
|
2022-10-25 |
2024-05-02 |
Nanovation Therapeutics Inc. |
LIPID NANOPARTICLE FORMULATIONS FOR ADMINISTRATION OF ANTISENSE OLIGONUCLEOTIDES
|
|
EP4608442A1
(en)
|
2022-10-28 |
2025-09-03 |
GlaxoSmithKline Biologicals S.A. |
Nucleic acid based vaccine
|
|
EP4612296A1
(en)
|
2022-10-31 |
2025-09-10 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
WO2024102677A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
TW202434728A
(zh)
|
2022-11-08 |
2024-09-01 |
美商旗艦先鋒創新有限責任公司 |
用於產生環狀多核糖核苷酸的組成物和方法
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
TW202425959A
(zh)
|
2022-11-08 |
2024-07-01 |
美商歐納醫療公司 |
遞送多核苷酸的脂質及奈米顆粒組合物
|
|
EP4622630A1
(en)
|
2022-11-21 |
2025-10-01 |
Translate Bio, Inc. |
Compositions of dry powder formulations of messenger rna and methods of use thereof
|
|
WO2024119103A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
IL320873A
(en)
|
2022-12-01 |
2025-07-01 |
Generation Bio Co |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions containing them
|
|
JP2025541726A
(ja)
|
2022-12-01 |
2025-12-23 |
ジェネレーション バイオ カンパニー |
細胞標的化のためのステルス脂質ナノ粒子組成物
|
|
JP2025540076A
(ja)
|
2022-12-01 |
2025-12-11 |
ジェネレーション バイオ カンパニー |
核酸、イオン化可能な脂質、ステロール、脂質アンカーポリマー、及びヘルパー脂質を含む脂質ナノ粒子、それらの使用
|
|
WO2024123134A1
(ko)
|
2022-12-09 |
2024-06-13 |
서울대학교산학협력단 |
B 세포 및 t 세포 내로 mrna를 전달하기 위한 펩타이드 기반 결합체를 포함하는 나노입자 및 이의 용도
|
|
KR20240087591A
(ko)
|
2022-12-09 |
2024-06-19 |
주식회사 나이벡 |
타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드 기반 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물
|
|
WO2024121814A1
(en)
|
2022-12-09 |
2024-06-13 |
Takeda Pharmaceutical Company Limited |
Modified immunomodulators
|
|
WO2024129988A1
(en)
|
2022-12-14 |
2024-06-20 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for delivery of therapeutic agents to bone
|
|
WO2024125597A1
(en)
|
2022-12-14 |
2024-06-20 |
Providence Therapeutics Holdings Inc. |
Compositions and methods for infectious diseases
|
|
WO2024126809A1
(en)
|
2022-12-15 |
2024-06-20 |
Sanofi |
Mrna encoding influenza virus-like particle
|
|
EP4634390A2
(en)
|
2022-12-15 |
2025-10-22 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
EP4637813A1
(en)
|
2022-12-20 |
2025-10-29 |
Sanofi Pasteur |
Rhinovirus mrna vaccine
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
JP2026504815A
(ja)
|
2022-12-29 |
2026-02-10 |
ポップヴァックス プライベート リミテッド |
マルチターゲットワクチンおよび治療剤
|
|
WO2024141784A2
(en)
|
2022-12-29 |
2024-07-04 |
Popvax Private Limited |
Broadly protective betacoronavirus vaccines and compositions
|
|
US12410394B2
(en)
*
|
2023-01-06 |
2025-09-09 |
Athergen, Inc. |
Composition comprising nicotinamide mononucleotide and leucomethylene blue
|
|
WO2024151673A2
(en)
|
2023-01-09 |
2024-07-18 |
President And Fellows Of Harvard College |
Recombinant nucleic acid molecules and their use in wound healing
|
|
TW202438673A
(zh)
|
2023-01-09 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
疫苗及相關方法
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024151685A1
(en)
|
2023-01-09 |
2024-07-18 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant nucleic acid molecules and their use in wound healing
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
EP4658239A1
(en)
|
2023-02-03 |
2025-12-10 |
GlaxoSmithKline Biologicals S.A. |
Rna formulation
|
|
WO2024163905A1
(en)
|
2023-02-03 |
2024-08-08 |
Genzyme Corporation |
Hsc-specific antibody conjugated lipid nanoparticles and uses thereof
|
|
WO2024167885A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|
|
CN120813562A
(zh)
*
|
2023-02-09 |
2025-10-17 |
斯奇络斯公司 |
可离子化阳离子化合物
|
|
EP4665736A2
(en)
|
2023-02-13 |
2025-12-24 |
Flagship Pioneering Innovations VII, LLC |
Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
JP2026507514A
(ja)
|
2023-02-17 |
2026-03-04 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
修飾されたシトシンを含むｄｎａ組成物
|
|
AU2024222598A1
(en)
|
2023-02-17 |
2025-07-31 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified uracil
|
|
JP2026509258A
(ja)
|
2023-03-08 |
2026-03-17 |
キュアバック エスイー |
核酸送達のための新規な脂質ナノ粒子製剤
|
|
WO2024192422A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
AU2024235803A1
(en)
|
2023-03-15 |
2025-09-25 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising polyribonucleotides and uses thereof
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
JP2026512425A
(ja)
|
2023-03-30 |
2026-04-16 |
オーエスイー・イミュノセラピューティクス |
免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
|
|
EP4687990A1
(en)
|
2023-03-30 |
2026-02-11 |
Ose Immunotherapeutics |
Method of synthesis of targeted lipid nanoparticle and uses thereof
|
|
AR132276A1
(es)
|
2023-04-07 |
2025-06-11 |
Takeda Pharmaceuticals Co |
Complejo de conjugación
|
|
JP2026514004A
(ja)
|
2023-04-12 |
2026-05-01 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
修飾されたｔｒｅｍ、組成物及びその関連方法
|
|
EP4695391A1
(en)
|
2023-04-12 |
2026-02-18 |
Flagship Pioneering Innovations VI, LLC |
Trems for use in correction of missense mutations
|
|
MX2025012337A
(es)
|
2023-04-17 |
2026-02-03 |
Sanofi Pasteur Inc |
Formulaciones de polvo seco reconstituibles y métodos de uso de las mismas
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
WO2024223728A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
EP4701657A1
(en)
|
2023-04-27 |
2026-03-04 |
GlaxoSmithKline Biologicals S.A. |
Influenza virus vaccines
|
|
AU2024269222A1
(en)
|
2023-05-05 |
2025-10-09 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
JP2026505939A
(ja)
|
2023-05-08 |
2026-02-20 |
メルク・シャープ・アンド・ドーム・エルエルシー |
ノロウイルスｖｐ１抗原をコードするポリヌクレオチドおよびその使用
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
DE102023001946A1
(de)
|
2023-05-12 |
2024-11-14 |
Friedrich-Schiller-Universität Jena, Körperschaft des öffentlichen Rechts |
Nanopartikel für den Transport von Wirkstoffen mit anionischen Gruppen, Verfahren zu deren Herstellung und deren Verwendung
|
|
WO2024236504A1
(en)
|
2023-05-15 |
2024-11-21 |
Takeda Pharmaceutical Company Limited |
Sequences and methods for delivery of dna and rna
|
|
WO2024236361A1
(en)
|
2023-05-15 |
2024-11-21 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for delivery of nucleic acids to cells
|
|
CN116270543B
(zh)
*
|
2023-05-19 |
2023-09-26 |
清华大学 |
脂质纳米颗粒在制备通过雾吸或鼻滴给药递送核酸的药物中的用途
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
AU2024279278A1
(en)
|
2023-05-31 |
2025-12-18 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
TW202513091A
(zh)
|
2023-06-09 |
2025-04-01 |
美商默沙東有限責任公司 |
用於人類乳突病毒疫苗之奈米乳液佐劑組合物
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
TW202517669A
(zh)
|
2023-07-05 |
2025-05-01 |
日商武田藥品工業股份有限公司 |
用於Ａ型血友病之基因療法的編碼表現增加之重組ＦＶｌｌｌ變異體的病毒載體
|
|
WO2025012756A1
(en)
|
2023-07-07 |
2025-01-16 |
Pfizer Inc. |
Amphiphilic tlr7/8 adjuvants and uses thereof
|
|
CN121532514A
(zh)
|
2023-07-07 |
2026-02-13 |
上海环码生物医药有限公司 |
用于季节性流感的环状rna疫苗及使用方法
|
|
US20250092426A1
(en)
|
2023-07-25 |
2025-03-20 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
|
US20250243274A1
(en)
*
|
2023-07-31 |
2025-07-31 |
Jibe Therapeutics, Inc. |
Compositions for Redirecting Immunoglobulins to Immune Cells
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
CN121620589A
(zh)
|
2023-08-01 |
2026-03-06 |
法国居里学院 |
包含编码环gmp-amp合酶的核酸序列的纳米粒子
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
TW202525266A
(zh)
|
2023-09-18 |
2025-07-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
可電離類脂質組成物及其治療用途
|
|
CN121909024A
(zh)
*
|
2023-09-22 |
2026-04-21 |
国立大学法人东北大学 |
包封有核酸的配体修饰脂质纳米颗粒的制造方法
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2025106670A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
TW202523695A
(zh)
|
2023-11-22 |
2025-06-16 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於治療非酒精性脂肪性肝病之方法及組成物
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025129128A1
(en)
|
2023-12-15 |
2025-06-19 |
Vivasor, Inc. |
Compositions and methods for non-viral delivery of therapeutic compounds
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025133115A1
(en)
|
2023-12-21 |
2025-06-26 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising il-35
|
|
TW202545974A
(zh)
|
2024-01-26 |
2025-12-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫受體抑制蛋白及相關方法
|
|
TW202543581A
(zh)
|
2024-02-12 |
2025-11-16 |
美商艾伊拉醫療公司 |
遞送組成物
|
|
WO2025180874A1
(en)
*
|
2024-02-27 |
2025-09-04 |
Basf Se |
Substituted 1,3-dioxolane sulfates and their use
|
|
WO2025187760A1
(ja)
*
|
2024-03-07 |
2025-09-12 |
日東電工株式会社 |
脂質ナノ粒子
|
|
WO2025190300A1
(zh)
*
|
2024-03-13 |
2025-09-18 |
仁景(苏州)生物科技有限公司 |
脂质纳米颗粒及脂质纳米颗粒组合物
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025196065A1
(en)
|
2024-03-20 |
2025-09-25 |
Sanofi |
Novel homocysteine based lipids and their use for delivery of nucleic acids
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
CN118388360B
(zh)
|
2024-04-17 |
2025-04-04 |
北京悦康科创医药科技股份有限公司 |
含有苯环结构的长效脾靶向阳离子脂质化合物、包含其的组合物及用途
|
|
WO2025240680A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025250751A1
(en)
|
2024-05-31 |
2025-12-04 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2025252759A1
(en)
|
2024-06-03 |
2025-12-11 |
Bio-Sourcing |
Transient expression by lipid nanoparticle formulations
|
|
WO2025259931A1
(en)
|
2024-06-14 |
2025-12-18 |
Orbital Therapeutics, Inc. |
Compositions and methods for rna circularization
|
|
WO2026006203A2
(en)
|
2024-06-24 |
2026-01-02 |
Orbital Therapeutics, Inc. |
Compositions and methods for making circular rna
|
|
US20260000702A1
(en)
|
2024-06-26 |
2026-01-01 |
Flagship Pioneering Innovations Vii, Llc |
Therapeutic circular dna forms
|
|
WO2026003582A2
(en)
|
2024-06-27 |
2026-01-02 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2026008743A1
(en)
|
2024-07-02 |
2026-01-08 |
Sanofi Pasteur Inc. |
Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
|
|
WO2026015647A1
(en)
|
2024-07-09 |
2026-01-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
|
|
WO2026020171A2
(en)
|
2024-07-19 |
2026-01-22 |
Aera Therapeutics, Inc. |
Chimeric antigen receptor constructs
|
|
WO2026027887A2
(en)
|
2024-08-02 |
2026-02-05 |
Mina Therapeutics Limited |
Hbg1/2-sarna compositions and methods of use
|
|
WO2026033123A1
(en)
|
2024-08-08 |
2026-02-12 |
Sanofi Pasteur Inc. |
Lipid nanoparticle formulations for mrna delivery
|
|
WO2026055543A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Modified dna compositions and related methods
|
|
WO2026055547A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions and related methods
|
|
WO2026064313A1
(en)
|
2024-09-17 |
2026-03-26 |
Flagship Pioneering Innovations Vii, Llc |
Rna compositions and related methods
|
|
WO2026064512A1
(en)
|
2024-09-18 |
2026-03-26 |
Generation Bio Co. |
Polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
WO2026064753A1
(en)
|
2024-09-23 |
2026-03-26 |
Tune Therapeutics, Inc. |
Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing
|
|
WO2026072557A2
(en)
|
2024-09-24 |
2026-04-02 |
Genzyme Corporation |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
|
WO2026068705A1
(en)
|
2024-09-26 |
2026-04-02 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof
|
|
WO2026085300A1
(en)
|
2024-10-16 |
2026-04-23 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods
|
|
WO2026085495A1
(en)
|
2024-10-18 |
2026-04-23 |
Generation Bio Co. |
Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor
|
|
WO2026088119A1
(en)
|
2024-10-24 |
2026-04-30 |
Pfizer Inc. |
Lipidated tlr7/8 modulators as adjuvants and uses thereof
|
|
WO2026088120A1
(en)
|
2024-10-24 |
2026-04-30 |
Pfizer Inc. |
Lipidated tlr7/8 modulators as adjuvants and uses thereof
|
|
WO2026093414A1
(en)
|
2024-10-30 |
2026-05-07 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising membrane il-35
|
|
WO2026093616A1
(en)
|
2024-11-04 |
2026-05-07 |
Variant |
Nucleic acid encoding cone-rod homeobox (crx) protein, and expression vectors thereof, for use in treating a ciliopathy
|